Should you buy Aptevo Therapeutics stock now?
No, the technical signal for Aptevo Therapeutics is currently SELL. Aptevo Therapeutics trades at $2.37 as of 9/2/2026. The overall technical signal is: Strong Sell. The technical analysis shows the following: MACD is negative (bearish trend) at -0.479 with falling momentum (signal: -0.453); RSI is at 24.8 (oversold), which could point to a potential buying opportunity; the stock is in a short-term downtrend (price below the 20-day average); the analyst price target of $25.50 points to 975.9% upside. The stock is in a broader downtrend (below SMA50/SMA200). Buying in a downtrend is generally not recommended. This is a technical observation based on current data, not investment advice.
What is the price target for Aptevo Therapeutics stock?
The average analyst price target for Aptevo Therapeutics is $25.50. The current price is $2.37, which gives an upside of 975.9%. Based on this, the stock is considered undervalued. The fair value range (±10% of the price target) is between $22.95 and $28.05.
Is Aptevo Therapeutics a dividend stock?
No, Aptevo Therapeutics does not currently pay a dividend to shareholders. The company reinvests its profits in growth instead of paying dividends.
What is the risk of Aptevo Therapeutics stock?
Aptevo Therapeutics is rated as a stock in the risk category Extremely speculative. the annual standard deviation is 98.6%, which classifies the stock as Extremely speculative. In addition, an RSI of 24.8 signals oversold (potential bottom).
Is Aptevo Therapeutics overvalued?
No, Aptevo Therapeutics is considered undervalued based on the analyst price target (975.9% upside). Aptevo Therapeutics has the following valuation ratios: a P/E ratio of 0.0 (lowly valued), a P/S ratio of 2.7, a P/B ratio of 0.7. The analyst price target suggests that the stock is undervalued by 975.9%.
Is Aptevo Therapeutics overbought?
No, Aptevo Therapeutics is actually oversold with an RSI of 24.8 (below 30). The technical indicators show: RSI is at 24.8 (below the 30 mark), which actually signals the price is oversold – the opposite of overbought. In addition, the price is 22.5% below the 20-day average (short-term downtrend). In addition, MACD is negative with falling momentum (bearish). IMPORTANT: The stock is oversold in a downtrend. A low RSI in a downtrend is NOT a buy signal – the price can keep falling. Wait for a trend reversal before buying.
When is the next Aptevo Therapeutics earnings report?
The date of the next earnings report for Aptevo Therapeutics has not been published yet. Check the company's investor calendar for updates.
Is Aptevo Therapeutics shorted?
Yes, Aptevo Therapeutics is shorted with 4.5% of the free float sold short. This is a moderate level of short selling, within the normal range for most stocks. Data is updated daily based on official filings with the SEC.
Are insiders buying Aptevo Therapeutics stock?
No, insiders are not buying Aptevo Therapeutics shares – they are net sellers. Over the last 3 months, insiders have made 0 purchases and 2 sales. On a net basis, 9,377 $ worth of shares were sold. Across the last 7 reported transactions, the split is 1 purchases and 6 sales, with a net 2,225,942 $ sold. Active sellers include White Marvin L, Huebner Dirk, TANG KEVIN C. Insider selling can have several explanations (e.g. planned 10b5-1 sales, portfolio diversification or taxes), but sustained selling by several insiders is worth watching closely.
Is Aptevo Therapeutics a good stock?
Based on our total score, Aptevo Therapeutics is rated as a disastrous stock with a total score of 3 out of 100. The stock scores very low on value, quality and momentum – it is among the worst in our database. The score is made up of Quality: 3/100. In addition: analysts see 975.9% upside to the price target; technical signal: Strong Sell. Whether Aptevo Therapeutics is a good investment depends on your time horizon, risk profile and portfolio. This is a data-driven observation, not investment advice.
What is the outlook for Aptevo Therapeutics stock?
The outlook for Aptevo Therapeutics based on current data: the average analyst price target is $25.50 (+975.9%); the stock is in a downtrend (below SMA50 and SMA200); the P/E ratio is 0.0 (low – a possible value stock). Keep in mind that stock prices are affected by many factors, including earnings reports, the economy and market sentiment. Past returns are no guarantee of future returns.
Why is Aptevo Therapeutics stock falling?
Aptevo Therapeutics is falling right now. The technical indicators show: the price is 22.5% below the 20-day average; MACD is negative with falling momentum (bearish signal); insiders have mostly been selling the stock recently. For the latest context, see our technical analysis, insider section and news overview above.
How high can Aptevo Therapeutics go?
The average analyst price target for Aptevo Therapeutics is $25.50, which corresponds to a potential gain of 975.9% from the current price of $2.37. Keep in mind that price targets are estimates, not guarantees. Actual price moves depend on earnings, market conditions and unexpected events.
How low can Aptevo Therapeutics fall?
We lack enough history to give a specific floor for Aptevo Therapeutics. Remember: past price swings are no guarantee for the future — a stock can fall further than the last 52 weeks suggest, especially on profit warnings, sector crises or a market crash. Use stop-loss orders and spread your portfolio to limit losses in single stocks.
What does Aptevo Therapeutics do?
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX pla... The company belongs to the Healthcare sector, more specifically the Bioteknologi industry, is headquartered in USA, and is traded on the USA Stocks. See the key figures, earnings history and price development above to evaluate Aptevo Therapeutics as an investment.
Did Aptevo Therapeutics raise or lower its guidance?
Over the last 60 days we have not registered a guidance raise or cut from Aptevo Therapeutics. The company can still adjust its guidance at quarterly reports or between reports — see the earnings history and the news overview above.
Is Aptevo Therapeutics making money or losing money?
We have no current profitability data for Aptevo Therapeutics. See the latest report in the earnings history above.
Can Aptevo Therapeutics go bankrupt?
The bankruptcy risk of Aptevo Therapeutics is rated as elevated. Altman Z2 (a model for assessing financial distress) is -73.59 — that places the company in the weak zone. This is a probability based on the numbers, not a verdict — bankruptcy is not imminent. But the balance sheet is measurably weaker than average, so watch the debt, liquidity and possible capital raises. The Piotroski score (financial health 0-9, higher is better) is 2 — which is weak. Debt relative to equity is 228% (high). Remember: models like Altman Z2 are statistical — unexpected shocks (fraud, a sector collapse, lawsuits) can always happen. Spread your portfolio.
Does Aptevo Therapeutics have a lot of debt?
Yes, Aptevo Therapeutics has elevated debt relative to equity. The debt-to-equity ratio (D/E — interest-bearing debt to equity) is 228%. For the healthcare sector, anything above 150% counts as elevated — that raises the financial risk, especially if interest rates rise or earnings fall. In healthcare, 80-150% is typical — large pharma companies carry debt for research and acquisitions. Note: D/E levels are highly sector-specific — a bank at 300% debt is normal, a tech stock at 300% is extremely leveraged. Always compare with similar companies in the same sector.
